Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT02153229 2025-12-26

MPM-PDT

Phase 2 Active not recruiting

52 enrolled

Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

NCT07256002 2025-12-01

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

Active not recruiting

10,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Phase 3 Active not recruiting

200 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT07145333 2025-09-08

Drug-SNP

Phase 2/3 Active not recruiting

600 enrolled

Thoracic

SCLC

NCT01064466 2025-07-24

Drugs-SNPs

Phase 2/3 Active not recruiting

600 enrolled

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT04905316 2025-06-17

CHORUS

Phase 2 Active not recruiting

41 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02122185 2025-06-08

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

110 enrolled

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Pleural Effusion, Malignant

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT05633602 2025-05-28

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

838 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03710876 2025-05-20

INFINITE

Phase 3 Active not recruiting

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

45 enrolled

Thoracic

Lung Neoplasms

NCT06518018 2024-07-24

HIBIC-NSCLC

Active not recruiting

80 enrolled

Thoracic

Barakat syndrome, Carcinoma, Non-Small-Cell Lung

Clinical Trials

NIRVANA-LUNG

MPM-PDT

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Drug-SNP

Drugs-SNPs

CHORUS

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

INFINITE

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

HIBIC-NSCLC